ACM
STOK icon

Altium Capital Management’s Stoke Therapeutics STOK Stock Holding History

Altium Capital Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-48,000
Closed -$634K – 155
2022
Q2 		$634K Buy
+48,000
New +$729K 0.25% 88

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Altium Capital Management's STOK Position: Q3 2022 in Review

Altium Capital Management sold out of Stoke Therapeutics (STOK) in Q3 2022, closing a stake of 48,000 shares — an estimated $634K sold.

Altium Capital Management first reported a position in STOK in Q2 2022 and held it in 1 quarter. The position peaked at $634K in Q2 2022. 105 funds tracked by Wall St. Rank hold STOK as of Q3 2022.

  • Altium Capital Management reported no remaining Stoke Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Altium Capital Management sold 48,000 Stoke Therapeutics shares in Q3 2022, an estimated $634K.
  • Altium Capital Management first reported a position in Stoke Therapeutics in Q2 2022 and held it in 1 quarter.
  • Altium Capital Management's Stoke Therapeutics position peaked at $634K in Q2 2022.
  • 105 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2022.

Based on Altium Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.